VivoSim LabsFRA:4OR 38 Cash Ratio is 1.73 as of Dec. 2025, which is 85% below its 10-year median of 11.81. GuruFocus rates FRA:4OR with a GF Score™ of 38/100 and a GF Value™ of €9.41. The stock has 4 warning signs investors should review. Among 1,389 Biotechnology companies, VivoSim Labs ranks worse than 62.78% on this metric.
VivoSim Labs has a Cash Ratio of 1.73. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for VivoSim Labs's Cash Ratio or its related term are showing as below:
FRA:4OR'
s Cash Ratio Range Over the Past 10 Years
Min: 0.4 Med: 11.81 Max: 51.82
Current: 1.73
During the past 13 years, VivoSim Labs's highest Cash Ratio was 51.82. The lowest was 0.40. And the median was 11.81.
FRA:4OR's Cash Ratio is ranked worse than 62.78% of 1389
companies
in the Biotechnology industry
Industry Median: 2.93
vs FRA:4OR: 1.73
VivoSim Labs (FRA:4OR) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
VivoSim Labs Cash Ratio Related Terms
VivoSim Labs Cash Ratio Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, VivoSim Labs's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's Cash Ratio distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a Cash Ratio of 1.73 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on VivoSim Labs and its competitors. This is 85% below median its historical median of 11.81. Over the past decade, VivoSim Labs' Cash Ratio has ranged from 0.40 to 51.82. According to the industry distribution chart, VivoSim Labs ranks #872 out of 1389 companies in the Biotechnology industry, placing it in the top 62.8%.
Is VivoSim Labs' Cash Ratio too high?
VivoSim Labs' current Cash Ratio of 1.73 is 85% below median its 10-year median of 11.81. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 51.82. The Biotechnology industry median Cash Ratio is 2.93. VivoSim Labs' value of 1.73 is 41% below this industry median. Based on the distribution chart, VivoSim Labs ranks #872 out of 1389 companies in the Biotechnology industry, which is below the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Cash Ratio compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #872 out of 1389 companies for Cash Ratio. This places VivoSim Labs in the lower half of its industry. The industry median Cash Ratio is 2.93. VivoSim Labs' value of 1.73 is 41% below this benchmark. Historically, VivoSim Labs' own Cash Ratio has ranged from 0.40 to 51.82 over the past decade. While the company's 10-year median is 11.81 vs. the industry median of 2.93, VivoSim Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,389 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current Cash Ratio of 1.73 is 41% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current Cash Ratio is 1.73, which is 85% below median its own 10-year median of 11.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Cash Ratio of 1.73. The stock's GF Value™ is €9.41, compared to a current price of €3.49 — trading 62.9% below its estimated fair value. The current Cash Ratio is 1.73, which is 85% below median its 10-year median of 11.81 and 41% below the Biotechnology industry median of 2.93. VivoSim Labs' overall GF Score™ is 38/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Cash Ratio is 1.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 62.9% below its estimated GF Value™ of €9.41.
Key valuation signals for FRA:4OR:
Cash Ratio: 1.73 (85% below median its 10-year median of 11.81)
GF Value™: €9.41 vs. price of €3.49 (62.9% below fair value)
Industry Position: 41% below the Biotechnology median (#872 of 1389)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
38GF Score
Get the complete analysis for FRA:4OR
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
